Wall Street Zen Upgrades Ralliant (NYSE:RAL) to Buy

Ralliant (NYSE:RAL) was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday.

Several other research analysts also recently commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Ralliant in a report on Monday, May 4th. Barclays increased their target price on Ralliant from $52.00 to $67.00 and gave the company an “overweight” rating in a research note on Wednesday, May 13th. Morgan Stanley raised their target price on Ralliant from $45.00 to $68.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Zacks Research raised Ralliant from a “strong sell” rating to a “hold” rating in a research report on Monday, April 13th. Finally, Citigroup upped their price target on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a report on Wednesday, May 13th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $67.30.

Ralliant Stock Up 0.0%

Shares of Ralliant stock opened at $68.18 on Friday. Ralliant has a 12-month low of $37.27 and a 12-month high of $70.22. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. The stock has a 50 day moving average price of $55.62 and a two-hundred day moving average price of $50.52. The stock has a market capitalization of $7.63 billion and a P/E ratio of -6.23.

Ralliant (NYSE:RAL) last released its quarterly earnings results on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.08. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. The company had revenue of $534.60 million for the quarter. Ralliant’s revenue for the quarter was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities analysts expect that Ralliant will post 2.64 earnings per share for the current year.

Hedge Funds Weigh In On Ralliant

A number of hedge funds have recently modified their holdings of the stock. Allworth Financial LP raised its holdings in shares of Ralliant by 134.4% in the fourth quarter. Allworth Financial LP now owns 511 shares of the company’s stock valued at $26,000 after buying an additional 293 shares during the last quarter. Rothschild Investment LLC grew its stake in shares of Ralliant by 98.1% during the fourth quarter. Rothschild Investment LLC now owns 612 shares of the company’s stock valued at $31,000 after purchasing an additional 303 shares during the last quarter. Keybank National Association OH raised its position in Ralliant by 1.6% in the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock worth $1,001,000 after purchasing an additional 305 shares during the last quarter. UMB Bank n.a. lifted its holdings in Ralliant by 49.6% during the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock worth $50,000 after buying an additional 326 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its holdings in Ralliant by 1.5% during the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after buying an additional 329 shares in the last quarter.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.